Wedbush Maintains Outperform on Xenon Pharmaceuticals, Lowers Price Target to $55

Benzinga · 1d ago
Wedbush analyst Laura Chico maintains Xenon Pharmaceuticals (NASDAQ:XENE) with a Outperform and lowers the price target from $71 to $55.